Asli Subasioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Asli Subasioglu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alev Garip Acar
Hematology Clinic, İzmir Katip Çelebi University Atatürk Training and Research Hospital, 35170 İzmir, Turkey
1 shared publication - Demet Kiper Unal
Hematology Clinic, İzmir Katip Çelebi University Atatürk Training and Research Hospital, 35170 İzmir, Turkey
1 shared publication - Kadriye Bahriye Payzın
Department of Hematology, Faculty of Medicine, İzmir Katip Çelebi University, İzmir 35620, Türkiye
1 shared publication - Kemal Aygün
Division of Hematology, İzmir Atatürk Training and Research Hospital, İzmir 35360, Türkiye
1 shared publication - Roya Gasimli
Department of Medical Biology, Faculty of Medicine, Ege University , Izmir, Türkiye
1 shared publication - Saliha Aksun
İzmir Katip Çelebi Üniversitesi
1 shared publication
Latest Publications
- Open Access
- 27 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1796
Clinical Significance of MTHFR C677T and A1298C Polymorphisms in Adult Patients with ALL and NHL
Background/Objectives: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms may influence folate metabolism and DNA synthesis, potentially affecting disease characteristics and clinical outcomes in hematologic malignancies. This study investigated the associations of MTHFR C677T and A1298C polymorphisms with clinical features and survival outcomes in adult patients with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). Methods: A total of 92 adult patients with ALL or NHL treated with standard chemotherapy were retrospectively analyzed. MTHFR C677T and A1298C genotypes were determined using real-time polymerase chain reaction. Associations between genotypes and baseline clinical features, treatment response, toxicity, overall survival (OS), and progression-free survival (PFS) were examined. Results: The C677T heterozygous genotype was significantly associated with the presence of B symptoms (p = 0.027). No significant differences were observed across genotypes with respect to other baseline clinical features, treatment response, or treatment-related toxicity. In the overall cohort (ALL + NHL), OS and PFS did not differ significantly by C677T or A1298C genotypes. However, in the NHL cohort, carriers of the C677T variant demonstrated significantly shorter PFS (p = 0.048) and a non-significant trend toward lower OS. This association was also observed in the DLBCL subgroup for PFS (p = 0.043), with a similar non-significant trend observed for OS. Conclusions: Although MTHFR genotyping appears to have limited value for broad clinical stratification, the observed association between the C677T polymorphism and PFS in NHL—particularly in the DLBCL subgroup—suggests a potential subtype-specific relevance that warrants further validation in larger, disease-specific cohorts.
- 27 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (5) , 1796
Open AccessClinical Significance of MTHFR C677T and A1298C Polymorphisms in Adult Patients with ALL and NHL
Background/Objectives: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms may influence folate metabolism and DNA synthesis, potentially affecting disease characteristics and clinical outcomes in hematologic malignancies. This study investigated the associations of MTHFR C677T and A1298C polymorphisms with clinical features and survival outcomes in adult patients with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). Methods: A total of 92 adult patients with ALL or NHL treated with standard chemotherapy were retrospectively analyzed. MTHFR C677T and A1298C genotypes were determined using real-time polymerase chain reaction. Associations between genotypes and baseline clinical features, treatment response, toxicity, overall survival (OS), and progression-free survival (PFS) were examined. Results: The C677T heterozygous genotype was significantly associated with the presence of B symptoms (p = 0.027). No significant differences were observed across genotypes with respect to other baseline clinical features, treatment response, or treatment-related toxicity. In the overall cohort (ALL + NHL), OS and PFS did not differ significantly by C677T or A1298C genotypes. However, in the NHL cohort, carriers of the C677T variant demonstrated significantly shorter PFS (p = 0.048) and a non-significant trend toward lower OS. This association was also observed in the DLBCL subgroup for PFS (p = 0.043), with a similar non-significant trend observed for OS. Conclusions: Although MTHFR genotyping appears to have limited value for broad clinical stratification, the observed association between the C677T polymorphism and PFS in NHL—particularly in the DLBCL subgroup—suggests a potential subtype-specific relevance that warrants further validation in larger, disease-specific cohorts.